help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on March 29, 2007
Endocrinology, doi:10.1210/en.2007-0270
A more recent version of this article appeared on June 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/6/2635    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baron, R.
Right arrow Articles by Rawadi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baron, R.
Right arrow Articles by Rawadi, G.

Submitted on February 27, 2007
Accepted on March 21, 2007

Targeting the Wnt/{beta}-catenin Pathway to Regulate Bone Formation in the Adult Skeleton

Roland Baron* and Georges Rawadi

Yale University School of Medicine, New Haven CT, USA; Galapagos, 102 Route de Noisy, 93230 Romainville, France

* To whom correspondence should be addressed. E-mail: roland.baron{at}yale.edu.

The recent identification of a link between bone mass in humans and gain- or loss-of-function mutations in the Wnt co-receptor LRP5 (Osteoporosis Pseudoglioma Syndrome, High Bone Mass trait) or in the Wnt antagonist Sclerostin (Sclerosteosis, Van Buchem syndrome) has called the attention of academic and industry scientists and clinicians to the importance of this signaling pathway in skeletal biology and disease. Multiple genetic and pharmacological manipulations of Wnt signalling in mice have since then confirmed the central role of this pathway in regulating bone formation.




This article has been cited by other articles:


Home page
 BloodHome page
C. M. Edwards
Wnt signaling: bone's defense against myeloma
Blood, July 15, 2008; 112(2): 216 - 217.
[Full Text] [PDF]

Home page
 BloodHome page
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Blood, July 1, 2008; 112(1): 196 - 207.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
P. Bovolenta, P. Esteve, J. M. Ruiz, E. Cisneros, and J. Lopez-Rios
Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease
J. Cell Sci., March 15, 2008; 121(6): 737 - 746.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
P. t. Dijke, C. Krause, D. J. J. de Gorter, C. W.G.M. Lowik, and R. L. van Bezooijen
Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling
J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 31 - 35.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
T. J. Martin and K. W. Ng
New Agents for the Treatment of Osteoporosis
IBMS BoneKEy, November 1, 2007; 4(11): 287 - 298.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society